New Risk • May 23
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company. Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹11.15 (vs ₹7.80 in FY 2025) Full year 2026 results: EPS: ₹11.15 (up from ₹7.80 in FY 2025). Revenue: ₹8.95b (up 14% from FY 2025). Net income: ₹1.02b (up 48% from FY 2025). Profit margin: 11% (up from 8.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 16
SMS Pharmaceuticals Limited to Report Q4, 2026 Results on May 22, 2026 SMS Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 22, 2026 Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹368, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 423% over the past three years. Reported Earnings • Feb 09
Third quarter 2026 earnings released: EPS: ₹2.59 (vs ₹2.15 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.59 (up from ₹2.15 in 3Q 2025). Revenue: ₹2.14b (up 24% from 3Q 2025). Net income: ₹234.7m (up 29% from 3Q 2025). Profit margin: 11% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 62% per year whereas the company’s share price has increased by 63% per year. Duyuru • Jan 31
SMS Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 07, 2026 SMS Pharmaceuticals Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 07, 2026 Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹319, the stock trades at a trailing P/E ratio of 35.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 276% over the past three years. Reported Earnings • Nov 09
Second quarter 2026 earnings released: EPS: ₹2.84 (vs ₹1.67 in 2Q 2025) Second quarter 2026 results: EPS: ₹2.84 (up from ₹1.67 in 2Q 2025). Revenue: ₹2.44b (up 24% from 2Q 2025). Net income: ₹253.1m (up 80% from 2Q 2025). Profit margin: 10% (up from 7.2% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 03
SMS Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 08, 2025 SMS Pharmaceuticals Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 08, 2025 New Risk • Oct 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Share price has been volatile over the past 3 months (6.8% average weekly change). Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.40 per share Eligible shareholders must have bought the stock before 22 September 2025. Payment date: 29 October 2025. Payout ratio is a comfortable 5.1% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to ₹301, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 235% over the past three years. Declared Dividend • Aug 13
Dividend of ₹0.40 announced Dividend of ₹0.40 is the same as last year. Ex-date: 22nd September 2025 Payment date: 29th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (5% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 18% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Duyuru • Aug 12
SMS Pharmaceuticals Limited announces Annual dividend, payable on October 29, 2025 SMS Pharmaceuticals Limited announced Annual dividend of INR 0.4000 per share payable on October 29, 2025, ex-date on September 22, 2025 and record date on September 22, 2025. Duyuru • Aug 11
SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025 SMS Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2025. Reported Earnings • Aug 11
First quarter 2026 earnings released: EPS: ₹2.31 (vs ₹1.95 in 1Q 2025) First quarter 2026 results: EPS: ₹2.31 (up from ₹1.95 in 1Q 2025). Revenue: ₹1.97b (up 20% from 1Q 2025). Net income: ₹204.9m (up 24% from 1Q 2025). Profit margin: 10% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. New Risk • Aug 10
New major risk - Revenue and earnings growth Earnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk High level of debt (42% net debt to equity). Duyuru • Aug 02
SMS Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 09, 2025 SMS Pharmaceuticals Limited announced that they will report Q1, 2026 results at 12:08 PM, Indian Standard Time on Aug 09, 2025 Duyuru • Jun 03
SMS Pharmaceuticals Limited Announces Earnings Guidance for the Year 2026 SMS Pharmaceuticals Limiteda announced earnings guidance for the year 2026. For the year, the company expects revenue growth of 20%. Reported Earnings • May 31
Full year 2025 earnings released: EPS: ₹8.16 (vs ₹5.89 in FY 2024) Full year 2025 results: EPS: ₹8.16 (up from ₹5.89 in FY 2024). Revenue: ₹7.89b (up 11% from FY 2024). Net income: ₹691.4m (up 39% from FY 2024). Profit margin: 8.8% (up from 7.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 48% per year. Duyuru • May 23
SMS Pharmaceuticals Limited to Report Q4, 2025 Results on May 30, 2025 SMS Pharmaceuticals Limited announced that they will report Q4, 2025 results on May 30, 2025 New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risks High level of debt (49% net debt to equity). Share price has been volatile over the past 3 months (8.8% average weekly change). Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹218, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 122% over the past three years. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹2.15 (vs ₹1.36 in 3Q 2024) Third quarter 2025 results: EPS: ₹2.15 (up from ₹1.36 in 3Q 2024). Revenue: ₹1.75b (up 8.7% from 3Q 2024). Net income: ₹182.4m (up 59% from 3Q 2024). Profit margin: 10% (up from 7.1% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 05
SMS Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 12, 2025 SMS Pharmaceuticals Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 09
Second quarter 2025 earnings released: EPS: ₹1.67 (vs ₹1.39 in 2Q 2024) Second quarter 2025 results: EPS: ₹1.67 (up from ₹1.39 in 2Q 2024). Revenue: ₹1.98b (up 19% from 2Q 2024). Net income: ₹141.0m (up 20% from 2Q 2024). Profit margin: 7.1% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Duyuru • Nov 08
SMS Pharmaceuticals Limited Approves Reconstitution of Committees SMS Pharmaceuticals Limited at its board meeting held on November 8, 2024, approved reconstitution of the Nomination and Remuneration Committee of the Board with effect from November 8, 2024 with the following members: Mrs. Shanti Sree Bolleni, Chairman and Dr. Suresh Kumar Gangavarapu and Dr. Sunkara Venkata Satya Shiva Prasad as Members. Duyuru • Nov 01
SMS Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 08, 2024 SMS Pharmaceuticals Limited announced that they will report Q2, 2025 results on Nov 08, 2024 Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹290, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 109% over the past three years. Upcoming Dividend • Sep 16
Upcoming dividend of ₹0.40 per share Eligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 6.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). New Risk • Aug 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 7.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change). Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹357, the stock trades at a trailing P/E ratio of 53x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 113% over the past three years. Declared Dividend • Aug 07
Dividend increased to ₹0.40 Dividend of ₹0.40 is 33% higher than last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (7% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 06
First quarter 2025 earnings released: EPS: ₹1.95 (vs ₹1.10 in 1Q 2024) First quarter 2025 results: EPS: ₹1.95 (up from ₹1.10 in 1Q 2024). Revenue: ₹1.64b (up 22% from 1Q 2024). Net income: ₹164.8m (up 76% from 1Q 2024). Profit margin: 10.0% (up from 6.9% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Duyuru • Jul 29
SMS Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 05, 2024 SMS Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 05, 2024 Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹277, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹260, the stock trades at a trailing P/E ratio of 44.2x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 48% over the past three years. Duyuru • May 31
SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-2024 SMS Pharmaceuticals Limited announced that at its board meeting held on 29 May 2024, recommended the dividend of INR 0.40 (40%) per equity share of face value of INR 1 each for the financial year 2023-2024, subject To Approve the members at the upcoming Annual General Meeting (AGM). The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course. Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹5.89 (vs ₹0.83 loss in FY 2023) Full year 2024 results: EPS: ₹5.89 (up from ₹0.83 loss in FY 2023). Revenue: ₹7.14b (up 37% from FY 2023). Net income: ₹498.3m (up ₹568.9m from FY 2023). Profit margin: 7.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Duyuru • May 24
SMS Pharmaceuticals Limited to Report Q4, 2024 Results on May 29, 2024 SMS Pharmaceuticals Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹206, the stock trades at a trailing P/E ratio of 48.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past three years. Duyuru • Mar 19
SMS Pharmaceuticals Limited announced that it has received INR 285.75 million in funding from Potluri Infra Projects Private Limited On March 19, 2024, SMS Pharmaceuticals Limited, closed the transaction. New Risk • Mar 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks High level of debt (51% net debt to equity). Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹182, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 42% over the past three years. Duyuru • Feb 09
SMS Pharmaceuticals Limited announced that it expects to receive INR 285.75 million in funding from Potluri Infra Projects Private Limited SMS Pharmaceuticals Limited announced a private placement of 9,000,000 common shares at a price of INR 31.75 per share for the gross proceeds of INR 285,750,000 on February 8, 2024. The transaction will include participation from new investor, Potluri Infra Projects Private Limited for 1,500,000 warrants, individual investors, Ramesh Babu Potluri for 2,500,000 warrants, Vamsi Krishna Potluri for 2,500,000 warrants, Trilok Potluri for 2,500,000 warrants. The transaction has been approved by the shareholders of the company. Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: ₹1.36 (vs ₹0.44 in 3Q 2023) Third quarter 2024 results: EPS: ₹1.36 (up from ₹0.44 in 3Q 2023). Revenue: ₹1.63b (up 9.5% from 3Q 2023). Net income: ₹114.8m (up 205% from 3Q 2023). Profit margin: 7.0% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Duyuru • Feb 03
SMS Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024 SMS Pharmaceuticals Limited announced that they will report Q3, 2024 results on Feb 08, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹1.39 (vs ₹0.24 loss in 2Q 2023) Second quarter 2024 results: EPS: ₹1.39 (up from ₹0.24 loss in 2Q 2023). Revenue: ₹1.67b (up 5.0% from 2Q 2023). Net income: ₹117.3m (up ₹137.3m from 2Q 2023). Profit margin: 7.0% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Duyuru • Nov 03
SMS Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023 SMS Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 08, 2023 Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.30 per share at 0.2% yield Eligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%). Duyuru • Aug 09
SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023 SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023. Reported Earnings • Aug 09
First quarter 2024 earnings released: EPS: ₹1.10 (vs ₹1.51 loss in 1Q 2023) First quarter 2024 results: EPS: ₹1.10 (up from ₹1.51 loss in 1Q 2023). Revenue: ₹1.36b (up 111% from 1Q 2023). Net income: ₹93.4m (up ₹221.1m from 1Q 2023). Profit margin: 6.9% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Duyuru • Aug 03
SMS Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023 SMS Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 08, 2023 Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Executive Director Vamsi Potluri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 26
Full year 2023 earnings released: ₹0.83 loss per share (vs ₹7.35 profit in FY 2022) Full year 2023 results: ₹0.83 loss per share (down from ₹7.35 profit in FY 2022). Revenue: ₹5.27b (up 1.4% from FY 2022). Net loss: ₹70.6m (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Duyuru • May 25
SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-2023 The board of directors of SMS Pharmaceuticals Limited at its AGM held on May 24, 2023, recommended the Dividend of INR 0.30 (30%) per equity share of face value of INR 1.00 each for the financial year 2022-23, subject To Approve the members at the upcoming annual general meeting. The AGM date and book closure/record date for the purpose of the payment of dividend will be informed in due course. Duyuru • May 19
SMS Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023 SMS Pharmaceuticals Limited announced that they will report Q4, 2023 results at 12:08 PM, Indian Standard Time on May 24, 2023 Reported Earnings • Feb 10
Third quarter 2023 earnings released: EPS: ₹0.44 (vs ₹1.07 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.44 (down from ₹1.07 in 3Q 2022). Revenue: ₹1.51b (up 22% from 3Q 2022). Net income: ₹37.6m (down 58% from 3Q 2022). Profit margin: 2.5% (down from 7.3% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Duyuru • Feb 01
SMS Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023 SMS Pharmaceuticals Limited announced that they will report Q3, 2023 results on Feb 09, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹0.24 loss per share (vs ₹2.72 profit in 2Q 2022) Second quarter 2023 results: ₹0.24 loss per share (down from ₹2.72 profit in 2Q 2022). Revenue: ₹1.60b (down 9.1% from 2Q 2022). Net loss: ₹20.1m (down 109% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 18% share price gain to ₹105, the stock trades at a trailing P/E ratio of 34.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 165% over the past three years. Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.30 per share Eligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 9.8% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%). Reported Earnings • Aug 18
First quarter 2023 earnings released: ₹1.51 loss per share (vs ₹2.78 profit in 1Q 2022) First quarter 2023 results: ₹1.51 loss per share (down from ₹2.78 profit in 1Q 2022). Revenue: ₹651.9m (down 60% from 1Q 2022). Net loss: ₹127.7m (down 154% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year. Reported Earnings • Jun 02
Full year 2022 earnings released: EPS: ₹7.35 (vs ₹7.39 in FY 2021) Full year 2022 results: EPS: ₹7.35 (down from ₹7.39 in FY 2021). Revenue: ₹5.25b (down 7.1% from FY 2021). Net income: ₹622.2m (flat on FY 2021). Profit margin: 12% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 17% share price gain to ₹112, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years. Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹1.07 (down from ₹2.53 in 3Q 2021). Revenue: ₹1.23b (down 18% from 3Q 2021). Net income: ₹89.6m (down 58% from 3Q 2021). Profit margin: 7.3% (down from 14% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 15
Second quarter 2022 earnings released: EPS ₹2.72 (vs ₹1.30 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹1.76b (up 34% from 2Q 2021). Net income: ₹230.3m (up 110% from 2Q 2021). Profit margin: 13% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue. Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.30 per share Eligible shareholders must have bought the stock before 22 September 2021. Payment date: 30 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Reported Earnings • Aug 09
First quarter 2022 earnings released: EPS ₹2.78 (vs ₹0.83 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.64b (up 45% from 1Q 2021). Net income: ₹235.6m (up 235% from 1Q 2021). Profit margin: 14% (up from 6.2% in 1Q 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improved over the past week After last week's 16% share price gain to ₹184, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 143% over the past three years. 
